Purpose Colorectal signet-ring cell carcinoma (SRCC) is rare, and very little detailed information on the molecular biology of the disease is available. Methods The literature on the clinical, pathological and, in particular, the molecular biology of this rare entity was critically reviewed. The reviewed articles take into account a total of 1,817 cases of SRCC, but only 143 cases have molecular data available. The characteristics of two patients with colorectal SRCC were also discussed. Results Colorectal SRCC mostly occurs in younger patients, is larger and has different site predilection compared with conventional colorectal adenocarcinoma. It can occur as one of the synchronous cancers in the colorectum. The cancer is usually diagnosed at advanced stages because of the late manifestation of symptoms, and aggressive treatment strategy is required. Limited reports in the literature have shown that the variant of colorectal cancer demonstrated a different pattern of genetic alterations of common growth kinase-related oncogenes (K-ras, BRAF), tumour suppressor genes (p53, p16), gene methylation and cell adhesion-related genes related to the Wingless signalling pathway (E-cadherin and beta-catenin) from conventional colorectal adenocarcinoma. Colorectal SRCC also showed high expression of mucin-related genes and genes related to the gastrointestinal system. There was also a higher prevalence of microsatellite instability-high tumours and low Cox-2 expression in colorectal SRCC as opposed to conventional adenocarcinoma. Conclusions Colorectal SRCC has unique molecular pathological features. The unique molecular profiles in SRCC may provide molecular-based improvements to patient management in colorectal SRCC.
Introduction
Signet-ring cell carcinoma (SRCC) is a rare type of adenocarcinoma characterised by mucin-secreting cancer cells that contain intracytoplasmic mucin. This form of carcinoma can occur in many sites in the body, but the most common site is in the stomach. SRCC in colorectum is rare, and the first case was reported by Laufman and Saphir in 1951 [1] . Because of this rarity, the characteristics of this tumour are seldom described in detail, and they have proved difficult to study. Most of the reported cases in the literature are either case reports or small series, and the rarity of the disease means that molecular characteristics are seldom mentioned. Thus, in this review, we presented the clinical and pathological features of two of our cases and reviewed the current perspectives of this entity.
Methods
A literature search was conducted using the PubMed database on topics related to SRCC with full-text articles published in English selected for review. The histological sections of all the colorectal cancer surgically removed in an 8-year period (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) ) in the Department of Surgery at James Cook University were reviewed by the authors (VG and AL). The clinical and pathological data of the cancers were recorded in a database for analysis. Of the 443 colorectal cancers reviewed, only two were SRCCs. A paraffin block was obtained from one case to perform immunohistochemical studies on molecular markers.
Case presentation
Case 1 A 73-year-old man underwent abdominal peritoneal resection for a cancer diagnosed on anal biopsy. His blood carcinoembryonic antigen (CEA) level was 1.3 ug/L (normal range, <5 ug/L). The cancer was 25 mm in extent, located at the lower part of the rectum and involved the anus. The pathological diagnosis was a SRCC (Fig. 1) . At the time of resection, the pathological staging was T4N1 (stage 3); however, liver metastases were detected within a month of the initial operation, raising the staging to 4. The patient died of the cancer 10 months after resection.
Case 2 A 76-year-old man underwent subtotal colectomy for synchronous carcinoma in the colon. He had a slightly elevated CEA level before operation (30 ug/L). At operation, a SRCC measuring 50 mm in maximum extent was noted in the ascending colon with a pathological staging of T3N0 (stage 2). In addition, there were three smaller cancers detected in the patient. These included a conventional moderately differentiated adenocarcinoma (T3N0, stage 2) in the transverse colon, a mucinous adenocarcinoma (T2N0, stage 1) in the caecum and a well-differentiated adenocarcinoma (T2N0, stage 1) also in the caecum. There were also several hyperplastic polyps at the colon and a flat adenoma in the caecum. The patient had no recurrence, and his CEA was within normal limits after the operation. He died of a bleeding gastric ulcer 65 months after the operation.
Immunohistochemical studies were performed on the SRCC. These showed that the tumour displayed nuclear positivity for p21 protein, and retinoblastoma (RB) protein with more than 90% of the cancer cells were positive for both proteins. The SRCC, however, was negative for p16, p53, hTERT and aurora kinase staining.
Discussion

Epidemiology
The true prevalence of SRCC is difficult to determine. In the larger series available, SRCC comprises approximately 0.1-2.6% of colorectal cancers noted [2] [3] [4] [5] [6] [7] . In our surgical series, SRCC comprised 0.45% of the primary resected colorectal cancer, being 0.4% (one of 251) of colonic cancer and 0.5% (one of 192) of rectal cancer.
SRCC has been mostly observed in younger age groups (≤40) than conventional colorectal adenocarcinoma and is more common in females [2] [3] [4] [5] [6] [7] . SRCC often presents at a more advanced stage lesions. The tumour is most common in the proximal colon, and Case 2 in our series was noted in the caecum. When found in the rectum, SRCC is usually located lower than in conventional adenocarcinoma [8] . Case 1 in our series was located in this region and was first detected by anal biopsy.
Findings in the USA showed that though the incidence of colorectal adenocarcinoma has been decreasing, the incidence of SRCC is still stable [6] . The incidence of SRCC in Caucasians is higher than African Americans and other ethnic groups, and colorectal SRCC is more common in patients with a long standing history of inflammatory bowel diseases or history of irradiation [6, 9, 10] .
Clinical manifestations and diagnosis
Characteristic features of colorectal SRCC include late manifestation of symptoms often resulting in diagnosis at advanced stages [11] . The presentations of colorectal SRCC include rectal bleeding, small bowel obstruction, abdominal pain, bloody stool, abdominal mass, vomiting, constipation and abdominal fullness, clinically mimicking Crohn's disease [5, 12, 13] . Delay in diagnosis perhaps caused by similarity to Crohn's disease reduces the chance of curative resection and increases the risk of local and distal metastases [8] . Diagnostic methods for colorectal SRCC are those used for conventional adenocarcinomas, with upper gastrointestinal endoscopy and barium enema that are useful for clinical differentiation of colorectal SRCC from Crohn's disease. Differentiating features for Crohn's disease include skipping longitudinal ulcer scar-like strictures, cobblestone appearance, segmental stricture and pseudo-sacculations. An emergency laparotomy may be the first diagnosis of SRCC if the tumour is obstructing the colon and producing acute symptoms [12] . Metastatic mucinous tumours of the female genital tract should also be differentiated from primary colorectal SRCC.
Metastasis
Rates of metastasis in SRCC are higher than those of conventional colorectal adenocarcinomas with the possible routes of metastasis being lymphatic and haematogenous and, commonly, peritoneal [4, 7, 12] . Sites involved in haematogenous metastasis of colorectal SRCC include bone, liver, uterus, prostate lung and skin [5, 7, [14] [15] [16] [17] . The most common sites of skin metastasis are abdominal wall and perineal area. An unusual presentation of colorectal SRCC with metastasis to upper lip has also been reported [17] . Metastasis is so common in SRCC that Anthony et al. reported that peritoneal carcinomatosis is the most common pattern of treatment failure in SRCC [2] .
Prognosis
In general, the 5-year survival rate in colorectal SRCC range from 0-12% in case groups ranging from four to 34 [3, 5, 18] Disease recurrence is also more frequent in colorectal SRCC compared to mucinous adenocarcinomas [18] . This high rate of recurrence and SRCC's poor prognosis may be the result of the generally advanced tumour stage at diagnosis rather than the disease's histology [8] . In our present series, the patient presenting with advanced disease survived less than a year, while the less advanced stage patient had long-term survival even with multiple synchronous cancers. It is thus likely the tumour staging is the best predictive factor for prognosis of colorectal SRCC.
In our previous study, which included colorectal mucinous adenocarcinoma and SRCC, it was found that factors like family history of colorectal cancer and expression status of p53 and p16 may predict the prognosis [19] ; however, only one case (Case 2 from the present study) was pure SRCC, and therefore the predictive impact of these markers in SRCC is unsure.
Management
Early diagnosis and aggressive treatment strategy is required for the management of primary colorectal SRCC [1] [2] [3] [4] [5] [6] [7] [8] . Surgical management for SRCC is similar to conventional colorectal adenocarcinoma. Chemotherapy and radiotherapy were used as adjuvant therapies for advanced disease.
Pathology
Macroscopic features
Tumour size of colorectal SRCC is usually larger when compared to conventional adenocarcinomas [8] . The most frequent presentation of SRCC is a scirrhous appearance and frequently a mucous appearance under macroscopic examination [7] . Synchronous cancer of the colorectum is uncommon and is infrequently reported for SRCC [2, 20] . Anthony et al. have reported 14% (four of 29) of patients with colorectal SRCC had synchronous cancers [2] . It is worth noting that Case 2 in our series had four synchronous cancers. The smaller cancers had a more favourable pathological stage than the indexed SRCC. It may be due to the presence of multiple tumours that the patient's disease was detected at stage 2 in, contrast to many SRCC. In addition, one of the other cancers in this patient was a mucinous adenocarcinoma, the overall pattern of subtypes in this individual being highly unusual.
Microscopic features
SRCC is characterised by abundant intracytoplasmic mucin. Due to the abundance of mucin, colorectal SRCC shows similarity with mucinous adenocarcinomas, though there are clinicopathological differences [19] . In SRCC, intracytoplasmic mucin pushes the nucleus to the periphery, giving an appearance like a signet ring. SRCC itself can be defined by the presence of these cells at >50% of total tumour cells with prominent intracytoplasmic mucin. Signet-ring cancer cells can occur in mucin pools of mucinous adenocarcinoma or in a diffusely infiltrative process with a minimal extracellular mucin. In some colorectal cancers, a combination of conventional glandular, mucinous and signet-ring cell morphologies can coexist in the same cancer (Fig. 2) . Other differential diagnoses of SRCC include metastases from other sites like the stomach, and in small biopsies, the diagnosis may be missed because the signet-ring cancer cells may be misinterpreted as foamy macrophages.
Molecular basis of SRCC
Little work has been done on the molecular aetiology of SRCC, but there has been some interest in examining several molecular signatures, including major oncogenic mutations such as in BRAF and K-ras. A slightly lower prevalence of K-ras mutation has been reported in SRCC compared to conventional adenocarcinomas, although Wistuba and colleagues detected a mutation at codon 61 in four of 16 SRCC cases that was not present in conventional adenocarcinoma [20] [21] [22] [23] [24] . In addition, a comparison study of nine colorectal SRCCs with 348 conventional colorectal adenocarcinomas revealed a higher frequency of BRAF mutation in colorectal SRCC than conventional adenocarcinoma (22% versus 8.6%) [24] . Thus, SRCC may have a distinct mutation pattern with respect to the main growth kinase pathways.
The p53 and p16 are tumour suppressor genes that are implicated in the development and progression of many cancers. In our Case 2, p53 and p16 protein expression was negative, although our previous study noted that some signet-ring tumour cells in mucinous adenocarcinoma were positive for p53 and p16 protein [19] . The loss of protein expression seen in Case 2 concurs with a study by Ogino and colleagues, who found loss of p16 protein expression in 25% (one of four) of colorectal SRCC [24] . Also, Mai et al. reported positive p53 immunohistochemical expression in 13 of the 15 colorectal SRCC [25] . In another study, 29% (two of nine cases) of SRCC were positive for p53 protein expression [23] . In addition, Wistuba and colleagues reported a lower level of p53 protein expression (40%, four of ten) in colorectal SRCC than in conventional colorectal adenocarcinoma [22] ; however, Ogino and colleagues have reported p53 protein expression in 75% (three of four) of SRCC [24] . This illustrates the difficulty in obtaining reliable molecular data for colorectal SRCC, as all these studies have relatively small numbers of cases, and no definite conclusions can be drawn. It has also been shown that p53 protein expression is usually stronger in the adenocarcinoma component rather than the signet-ring carcinoma component of SRCC [25] . It is possible that the variable expression of p16 and p53 seen in these studies is a result of differing percentages of signet-ring cancer cells in the various cases utilised. This may indicate that different percentage of signet-ring cells in SRCCs may themselves have altered biological behaviour.
HATH1, MUC2 and SOX2 are genes for regulation and production of mucin in the gastrointestinal tract. Park and colleagues studied the expression of the proteins for these genes in seven cases of colorectal SRCC [26, 27] . These proteins were frequently expressed in SRCC but rarely expressed in conventional adenocarcinoma, suggesting that mucin-related genes were related to the pathogenesis of colorectal SRCC. Sentani et al. reported expression of the mucin-related proteins, MUC2 (80%) and MUC5AC (38%, six of 16) in colorectal SRCC in results similar to those of Park et al. [26] [27] [28] .
Sentani et al. reported immunochemical expression of Reg IV and Claudin 18 in 16 cases of colorectal SRCC. They noted Reg IV in 100% (16 of 16) and Claudin 18 in 38% (six of 16) of colorectal SRCC [28] . Both are cancerrelated genes of the gastrointestinal system and have also been seen in SRCC in sites other than colorectum. They have been implicated in the carcinogenesis of SRCC, Cytosine methylation leads to inactivation of genes when their promoter regions carry CpG islands and is commonly found on various tumour suppressor genes in cancers. Ogino et al. reported relatively higher frequency of the CpG island methylator phenotype (CIMP) in colorectal SRCC (33%, two of six cases) compared to conventional adenocarcinoma (12%, 34 of 286) as detected by quantitative real time PCR [29] . This indicates that promoter methylation may play a significant role in the regulation of genes influencing the carcinogenesis or differentiation of colorectal SRCC.
E-cadherin plays a crucial role in cell to cell adhesion and in maintaining epithelial morphology. Reduction of expression of E-cadherin due to aberrant hypermethylation is important for metastases in cancer and loss of protein expression of E-cadherin was reported in 100% (four of four) cases of colorectal SRCC [30] . This loss of protein expression may contribute to the high grade and invasive nature of SRCC in colorectum. In addition, strong expression of methyl-CpG-binding protein (MeCP2) was detected in these four cases by in situ hybridization, and 75% (three of four) of these cases had methylation of the Ecadherin promoter region detected by methylation-specific PCR. This implies that the regulation of E-cadherin gene expression in colorectal SRCC commonly influenced promoter methylation, reinforcing the importance of the role of CIMP in the disease.
Klarskov et al. showed in a case of paired colorectal SRCC that the intramucosal, intraepithelial and stromal lesion cells of the cancer had a normal membranous expression of beta-catenin and E-cadherin [20] . Submucosally infiltrating cells, however, featured alterations to this pattern with loss of membranous expression of both proteins and nuclear accumulation of beta-catenin. Klarskov et al. suggested that a disruption of the Wingless signalling pathway takes place at the transition from the intramucosal to the submucosal level [20] . Conversely, however, the study by Wong et al. noted aberrant beta catenin localization in only two of 18 colorectal SRCC and concluded that there is no prominent role of the pathway in the colorectal SRCC [31] . Case series with higher numbers of invasive and high-stage colorectal SRCC will be needed to fully determine the significance of these changes.
Microsatellite instability (MSI) is caused by inactivation of a group of genes responsible for DNA mismatch repair. It is a major mechanism for pathogenesis of colorectal cancer. The study by Witsuba et al. found that 30% (three of ten) of SRCC cases were MSI-high tumours, with conventional adenocarcinoma showing slightly lower prevalence of MSI-high tumours (3 of 18; 17%) [22] . A separate study of eight cases of colorectal SRCC showed 25% (n=2) were MSI-high tumours whereas 11% (38 of 351) of conventional adenocarcinomas were MSI-high tumours [24] . These studies are small, but show good agreement of data, suggesting that colorectal SRCC are more likely to be MSI-high tumours than conventional adenocarcinoma.
COX-2 protein catalyses the conversion of arachidonic acid to prostaglandins and is related to the genesis and maintenance of colorectal cancers. Karnes et al. found reduced immunochemical staining of COX-2 in five cases of colorectal SRCC compared to other colorectal cancer subtypes and a significantly correlation with colorectal carcinomas showing signs of defective DNA repair mechanisms [32] . These findings indicate that colorectal SRCC may commonly feature defective DNA repair mechanisms, in relation to its higher rates of MSI. The defect may contribute to the poor prognosis of patients with colorectal SRCC.
In our current case study, we have presented for the first time the results of aurora kinase, hTERT, p21 and retinoblastoma (RB) protein expression in a case of SRCC. Aurora kinase is a regulator of mitosis, found to be more lowly expressed in colorectal mucinous adenocarcinoma than conventional adenocarcinoma in our previous study [33] . SRCC can be viewed as a variant of mucinous adenocarcinoma. The absence of expression in Case 2 may indicate that loss of aurora kinase is an event common to SRCC. The p21 protein is a downstream effector of the p53-specific pathway, found to be lost or expressed at a lower level in non-mucinous colorectal carcinoma in our previous study [34] . In Case 2, the high level of expression of p21 protein in SRCC shows a marked difference from non-mucinous colorectal carcinoma and is perhaps related to the relatively lower expression of p53 in SRCC found in other studies. This may be indicative of the different molecular characteristics of SRCC. Also, increased p21 expression may be common to colorectal SRCC and mucinous adenocarcinomas.
The hTERT expression may reflect the telomerase activity in a cancer. It is worth noting that control of hTERT expression by endogenous p53 was demonstrated to be indirect and mediated by p21 and RB/E2F pathways in cancer cell lines [35] . RB is a tumour suppressor that is commonly expressed in colorectal cancer [36] . In our previous study, we noted higher levels of hTER expression in patients with stage 4 colorectal adenocarcinoma [34] . Case 2 of the SRCCs in our series showed negative expression of hTERT and high level of expression of RB proteins. It is difficult to draw conclusions from the findings in one case. The low stage of Case 2 (stage 2) may account for the lack of hTERT protein staining. On the other hand, the increased p21 and RB staining may indicate some early disruption of the regulatory pathways for hTERT activity.
Conclusions
In summary, SRCC occurs in younger age groups and more distant portions of the colorectum than conventional adenocarcinoma. Clinically, SRCC presents later, with more advanced stages and with higher incidence of metastases, including to the peritoneum, than conventional colorectal adenocarcinoma. Limited reports in the literature have shown that this variant of colorectal cancer demonstrates a different pattern of genetic behaviour from conventional colorectal adenocarcinoma. In the category of oncogenes and tumour suppressors, SRCC showed a lower prevalence of K-ras mutation, expression of p16 and p53 proteins and a higher prevalence of BRAF mutation and CIMP than conventional colorectal adenocarcinoma. In addition, colorectal SRCC showed high expression of mucin-related genes, a higher prevalence of MSI-high tumours and reduced Cox-2 expression in colorectal SRCC compared to conventional adenocarcinoma. Thus, the overall clinical and molecular differences between these two groups support the notion that colorectal SRCC is an independent disease subtype.
The available molecular studies in colorectal SRCC are hampered by the low incidence of SRCC and thus the low availability of tissue for study. Because of this, several studies have shown conflicting or ambiguous results, strongly demonstrating the need for larger series to improve our understanding of the pathogenesis of this cancer subtype. Trends, however, have begun to emerge from the molecular studies, in particular related to the loss of DNA repair mechanisms. These trends will inform future research into SRCC and may provide the first molecular-based improvements to patient management in colorectal SRCC.
